Navigation Links
DMP1 deletion cooperates with oncogenic K-ras in lung cancer
Date:10/15/2007

Scientists have identified the transcription factor DMP1 as a pivotal tumor suppressor for both human and mouse lung cancers, especially in carcinomas that exhibit intact Arf-p53 pathways. The research, published by Cell Press in the October 2007 issue of Cancer Cell, may lead to development of new drug therapies for lung cancer.

Lung cancer is the leading cause of cancer deaths in the world, responsible for 1.3 million deaths each year. Non-small-cell lung cancers (NSCLCs) are the most common type of lung cancer, and scientists have identified distinct patterns of genetic alterations that are associated with this malignancy. Mutations that activate the oncogene K-ras or interfere with the tumor suppressors p53 and Arf are common in human NSCLCs. The mouse model K-rasLA had previously been developed based on this knowledge and is an excellent system for studying human NSCLC.

Dmp1 is a unique tumor suppressor that activates Arf expression and thus induces p53-dependent cell cycle arrest. Mice lacking the gene for Dmp1 commonly develop lung tumors, and Dmp1 has been identified as a regulator of the Arf-p53 pathway in vitro. In striking contrast to the accumulating information on mouse Dmp1, very little is known about the involvement of human DMP1 (hDMP1) in cancer, says lead author Dr. Kazushi Inoue of Wake Forest University. Dr. Inoue and colleagues conducted a study designed to investigate the collaborative effects of Dmp1 deletion and K-ras activation in the genesis and progression of lung cancer.

Tumorigenesis was significantly accelerated in K-rasLA mice that were lacking one or both copies of Dmp1. The researchers demonstrated that Dmp1 also showed haploid insufficiency, meaning that cancer developed even when one copy of the gene was present, in samples from lung cancer patients with non-small-cell lung cancers. Further, in K-rasLA mice, lung carcinomas were associated with either p53 mutations or deletion of Dmp1 to inactivate the Arf-p53 pathway. Consistent with this finding, human lung carcinomas exhibited loss of hDMP1 in a mostly exclusive fashion with loss of Arf-p53 activation. Importantly, Dmp1 overexpression inhibited growth of human lung cancer cells with K-ras mutation and wild-type Arf and p53.

These findings suggest that DMP1 plays a critical role in the development of lung cancer. We have demonstrated that the hDMP1 gene is hemizygously deleted in a significant percentage of mouse and human non-small-cell lung carcinomas, especially those which retained the intact Arf-p53 pathway, explains Dr. Inoue. Since hDMP1 loss-of-heterozygosity lung cancer cells retain one allele of the hDMP1 locus, this gene might be a promising target for future drug development.


'/>"/>
Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Vitamin B12 can help in detecting cancers
6. More Accurate "PROSTATE CANCER" Test can save Unnecessary Biopsies
7. Consensus on "Combination Therapy" for Breast Cancer
8. Cancers of Colon & Rectum linked to Cigarette Smoking
9. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
10. The Cancer Rumour mill working over time
11. Want skin cancer? Please have a cigarette
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... of the GlycoMark test throughout the Northeast U.S. , GlycoMark is the ... diabetes. The GlycoMark test provides a clinically proven one- to two-week measure of ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, a leading ... Nova Skin Sciences division, recently announced the launch of Allumière Antiaging Cream, a ... of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract and Vitamin ...
(Date:4/27/2017)... and DENVER (PRWEB) , ... April 27, 2017 ... ... Health, the nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement ... is enabled by the continuing support of the Jane and Leonard Korman Family ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology: